Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 439
  • Shares Outstanding, K 2,986
  • Annual Sales, $ 7,770 K
  • Annual Income, $ -116,660 K
  • 60-Month Beta 2.09
  • Price/Sales 0.42
  • Price/Cash Flow N/A
  • Price/Book 0.07
Trade TNXP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -110.98
  • Most Recent Earnings $-19.28 on 08/16/24
  • Next Earnings Date 08/15/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -2.03
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -3.66
  • Prior Year -58.47
  • Growth Rate Est. (year over year) +96.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1313 +10.59%
on 09/06/24
0.8456 -82.83%
on 08/19/24
-0.3022 (-67.55%)
since 08/16/24
3-Month
0.1313 +10.59%
on 09/06/24
1.3725 -89.42%
on 06/20/24
-1.0748 (-88.10%)
since 06/18/24
52-Week
0.1313 +10.59%
on 09/06/24
28.3168 -99.49%
on 09/19/23
-27.3812 (-99.47%)
since 09/18/23

Most Recent Stories

More News
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801

World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years Worldwide availability and affordability...

TNXP : 0.1451 (-1.29%)
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END

TNXP : 0.1451 (-1.29%)
LLY : 904.97 (-0.13%)
PFE : 29.75 (-0.27%)
ABBV : 192.94 (-0.26%)
AXSM : 91.54 (+0.66%)
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

TNXP : 0.1451 (-1.29%)
LLY : 904.97 (-0.13%)
PFE : 29.75 (-0.27%)
ABBV : 192.94 (-0.26%)
AXSM : 91.54 (+0.66%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

TNXP : 0.1451 (-1.29%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
ABBV : 192.94 (-0.26%)
MRK : 118.64 (+0.30%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

TNXP : 0.1451 (-1.29%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
ABBV : 192.94 (-0.26%)
MRK : 118.64 (+0.30%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease

A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...

OPTI.CN : 0.2800 (-3.45%)
SEEL : 0.1991 (-11.51%)
NUMI.TO : 0.0350 (+16.67%)
NUMIF : 0.0236 (-1.67%)
ATAI : 1.2400 (-3.13%)
OPTHF : 0.2051 (-3.71%)
TNXP : 0.1451 (-1.29%)
TAK : 14.82 (-0.20%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...

SEEL : 0.1991 (-11.51%)
TAK : 14.82 (-0.20%)
ATAI : 1.2400 (-3.13%)
TNXP : 0.1451 (-1.29%)
OPTI.CN : 0.2800 (-3.45%)
OPTHF : 0.2051 (-3.71%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease

/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten...

OPTI.CN : 0.2800 (-3.45%)
OPTHF : 0.2051 (-3.71%)
SEEL : 0.1991 (-11.51%)
TAK : 14.82 (-0.20%)
ATAI : 1.2400 (-3.13%)
TNXP : 0.1451 (-1.29%)
Psychedelics Use Among Young Adults Reaches All-Time High

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever.  According to a National Institute of Health...

OPTI.CN : 0.2800 (-3.45%)
OPTHF : 0.2051 (-3.71%)
SEEL : 0.1991 (-11.51%)
NUMI.TO : 0.0350 (+16.67%)
NUMIF : 0.0236 (-1.67%)
ATAI : 1.2400 (-3.13%)
TNXP : 0.1451 (-1.29%)
Psychedelics Use Among Young Adults Reaches All-Time High

/PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to...

OPTI.CN : 0.2800 (-3.45%)
NUMI.TO : 0.0350 (+16.67%)
OPTHF : 0.2051 (-3.71%)
SEEL : 0.1991 (-11.51%)
NUMIF : 0.0236 (-1.67%)
ATAI : 1.2400 (-3.13%)
TNXP : 0.1451 (-1.29%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 0.1637
2nd Resistance Point 0.1563
1st Resistance Point 0.1517
Last Price 0.1451
1st Support Level 0.1397
2nd Support Level 0.1323
3rd Support Level 0.1277

See More

52-Week High 28.3168
Fibonacci 61.8% 17.5499
Fibonacci 50% 14.2240
Fibonacci 38.2% 10.8982
Last Price 0.1451
52-Week Low 0.1313

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar